Recent Research Analysts’ Ratings Updates for Kura Oncology (KURA)

A number of research firms have changed their ratings and price targets for Kura Oncology (NASDAQ: KURA):

• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Raymond James Financial, Inc..
• 8/24/2026 – Kura Oncology was given a new $24.00 price target by Morgan Stanley.
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/24/2026 – Kura Oncology had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $24.00 price target on the stock.
• 8/13/2026 – Kura Oncology had its price target raised by Wedbush from $36.00 to $38.00. They now have an “outperform” rating on the stock.
• 7/28/2026 – Kura Oncology had its “outperform” rating reaffirmed by Wedbush. They now have a $36.00 price target on the stock.
• 7/17/2026 – Kura Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brian T. Powl sold 4,345 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the completion of the transaction, the insider owned 169,269 shares of the company’s stock, valued at approximately $2,012,608.41. This trade represents a 2.50% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is currently owned by company insiders.

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.